Enfuvirtide, a new treatment for HIV infection
Canadian Coordinating Office for Health Technology Assessment
Record ID 32003000843
English, French
Authors' objectives:
To summarize the available information on the use of enfuvirtide - also called pentafuside or T-20 - (sold as Fuzeon(TM), manufactured by Hoffmann-La Roche), for the treatment of patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.
Authors' recommendations:
The addition of enfurvitide to a failing antiretroviral regimen sustains the clinical response over one year. Long-term efficacy and safety studies are needed to determine this drug's place in therapy. The current recommendation is to limit its use to heavily treatment-experienced patients. An open-label phase III study is underway to assess serious adverse events.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca
Year Published:
2003
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Costs and Cost Analysis
- Anti-HIV Agents
- HIV Fusion Inhibitors
- HIV Infections
- Peptide Fragments
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.